Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study

Leighl, N. B.Shu, C. A.Minchom, A.Felip, E.Cousin, S.Cho, B. C.Park, K.Han, J-Y.Boyer, M.Lee, C. K.Moreno Garcia, V.Tomasini, P.Viteri, S.Xie, J.Mertz, J.Artis, E.Schnepp, R. W.Knoblauch, R. E.Thayu, M.Trigo Perez, J. M.2025-01-072025-01-072021-09-210923-7534https://hdl.handle.net/10668/26937enAmivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS studyconference outputopen access10.1016/j.annonc.2021.08.17971569-8041https://doi.org/10.1016/j.annonc.2021.08.1797700527702211